BioCentury
ARTICLE | Clinical News

Mirati reports updated confirmed ORR of 16% in Phase II of sitravatinib for NSCLC

October 26, 2018 6:46 PM UTC

Mirati Therapeutics Inc. (NASDAQ:MRTX) reported data from 56 evaluable patients with checkpoint-refractory non-small cell lung cancer in a Phase II trial showing that its once-daily oral receptor tyrosine kinase (RTK) inhibitor sitravatinib (MGCD516) plus PD-1 inhibitor Opdivo nivolumab led to a confirmed overall response rate (ORR) of 16%, including nine complete (CR) or partial responses (PR). The confirmed ORR is about the same as the company reported in 23 evaluable patients in April.

The company said the combination also led to two unconfirmed CRs/PRs in a pair of patients that remain on trial and are awaiting confirmation, and five unconfirmed CRs/PRs that will remain unconfirmed as the patients came off study. A preliminary estimate for median duration of response was more than nine months, and 18 patients showed tumor reductions of over 30%...